

CURRICULUM VITAE

Name:

Dr. Saswata Saha

Permanent Address:

Gurupally (Dakshin), P.O. Santiniketan,
Bolpur, Dist. Birbhum, West Bengal
PIN- 731235

Present Address:

Madhumalancha Complex, Block C, 4th
Floor, Flat No. 501
262, Pulin Avenue, P.O. Rajbari Colony
North 24 Parganas, PIN- 700081

E-mail:

saswataonline@gmail.com

Mobile Number:

(+91)9475241995

Medical Education:

Graduation (2008-2014)

**MBBS from Medical College, Kolkata,
West Bengal**

Post-Graduation (2015-2018)

**MD in General Medicine
Institute of Medical Sciences, BHU
Varanasi, UP**

Super-Specialisation (2019-2022)

**DM in Medical Oncology
Tata Memorial Centre, Parel
Mumbai, Maharashtra**

Fellowship (2023-2024)

**One Year TMC Fellowship in Bone
Marrow Transplantation in the department
of Medical Oncology at ACTREC, Tata
Memorial Centre, Navi Mumbai**

Clinical Experience details:

23rd March 2013 – 22nd March 2014

**One-year Compulsory Residential Rotating
Housephysicianship (Internship) in the
different disciplines of Medical College &
Hospital, Kolkata**

1st April 2014 – 31st March 2015

**Stipendiary House Physician in the
department of Neuro Medicine at Medical
College, Kolkata**

9th August 2018 – 1st January 2019

Senior Resident in the department of Medical Oncology at VMMC & Safdarjung Hospital, New Delhi

1st August 2022 – 31st July 2023

Bonded Ad-hoc Assistant Professor in the department of Medical Oncology at Tata Memorial Hospital, Mumbai

4th November 2024 – present

Junior Consultant in the department of Clinical Haematology & Cellular Therapies at Tata Medical Center, Kolkata

Memberships:

- A. Indian Society of Medical and Pediatric Oncology**
- B. European Society for Medical Oncology**
- C. American Society of Clinical Oncology**

Awards:

- A. Quiz Winner 3rd Masterclass in Lung Cancer 2020**
- B. Zonal Round Participant ISMPO TYSA – 9th Edition**
- C. Winner Sunday MHG quiz (January 8, 2023)**
- D. IMAGE Journal Club and Journal Scan Eagle Eye Competition Winner (25th May, 2023)**
- E. IMAGE Journal Club and Journal Scan Eagle Eye Competition Winner (27th July, 2023)**
- F. IMAGE Quiz Competition Winner (27th July, 2023)**
- G. IMAGE Journal Club and Journal Scan Eagle Eye Competition Winner (24th August, 2023)**
- H. 3rd Prize in Mini-Oral Presentation at the 6th Annual Conference of IMAGE “IMC 2024”**
- I. IMAGE Journal Club and Journal Scan Eagle Eye Competition Winner (26th**

December, 2024)

Publications:

A. Saswata Saha, Sandesh M. Raykar, Chandan Kumar, Lalit P. Meena, Jaya Chakravarty, Madhukar Rai, Shyam Sundar. Spontaneous Chest Wall Hematoma – An uncommon presentation of Chronic Myeloid Leukemia. European Journal of Biomedical and Pharmaceutical Sciences. Volume 5, Issue 5, p874-878 2018.

B. Saha S, Meena LP, Chakravarty J, Rai M. Role of B-type natriuretic peptide level in predicting future cardiac events in patients presenting with dyspnea (a hospital-based study). Heart India 2019;7:49-54.

C. Kashyap L, Patil V, Noronha V, Joshi A, Menon N, Jobanputra K, **Saha S**, Chaturvedi P, Banavali SD, Prabhash K. Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC). Ecancermedicalsecience. 2021 Dec 2;15:1325.

D. Patil V, Noronha V, Dhumal SB, Joshi A, Menon N, Bhattacharjee A, Kulkarni S, Ankathi SK, Mahajan A, Sable N, Nawale K, Bhelekar A, Mukadam S, Chandrasekharan A, Das S, Vallathol D, D Souza H, Kumar A, Agrawal A, Khaddar S, Rathnasamy N, Shenoy R, Kashyap L, Rai RK, Abraham G, **Saha S**, Majumdar S, Karuvandan N, Simha V, Babu V, Elamarthi P, Rajpurohit A, Kumar KAP, Srikanth A, Ravind R, Banavali S, Prabhash K. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel- group, non-inferiority, randomised, phase 3 trial. Lancet Glob Health. 2020. Sep;8(9):e1213-e1222.

E. Saha, Saswata; Joshi, Amit; Noronha, Vanita; Patil, Vijay; Menon, Nandini; Singh,

Ajay; Shetty, Omsree; Mittal, Neha; Chandrani, Pratik; Chougule, Anuradha; Prabhash, Kumar. NRAS mutation in differentiated thyroid cancer. *Cancer Research, Statistics, and Treatment* 5(4):p 722-727, Oct–Dec 2022.

F. Kashyap, Lakhan; **Saha, Saswata**; Srikanth, Anne. Dabrafenib: A narrative drug review. *Cancer Research, Statistics, and Treatment* 3(3):p 537-544, Jul–Sep 2020.

G. Saswata Saha, Vijay M. Patil, Vanita Noronha, Nandini Menon, Ajay Kumar Singh, Mannavi Suman, Amit Agrawal, Satvik Khaddar, Shatabdi Chakraborty, Prathamesh S. Pai, Devendra A. Chaukar, Pankaj Chaturvedi, Sarbani Ghosh Laskar, Kumar Prabhash. Neoadjuvant Chemotherapy in Rare Type of very locally advanced Sinonasal Carcinomas – Long term results from a Tertiary Care Center. *ecancer* 17 1549.

H. Saha S, Patil VM, Noronha V, Menon N, Kumar Singh A, Patlekar G, Yadav N, Pai PS, Chaukar DA, Chaturvedi P, Ghosh Laskar S, Prabhash K. Real world data on long term outcome of neoadjuvant chemotherapy in locally advanced esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation - Results from a single centre study. *Oral Oncol.* 2023 Jul 4;144:106486.

I. Rai, Rahul K.; Patil, Vijay M.; Alone, Mitali; **Saha, Saswata**; Tudu, Rajanigandha; Noronha, Vanita; Parekh, Deevyashali S.; Menon, Nandini; Ghosh-Laskar, Sarbani; Pai, Prathamesh; Prabhash, Kumar. Neoadjuvant chemotherapy in locally advanced (T3-T4) external auditory canal carcinoma: A retrospective observational study. *Cancer Research, Statistics, and Treatment* 6(1):p 120-122, Jan–Mar 2023.

J. Z. Peelay, **S. Saha**, V. Patil, N. Menon, A. Singh, M. Shah, A. Sahu, A. Ubharay, O.R. Chowdhury, K. Prabhash, V. Noronha. Neoadjuvant Chemotherapy in Locally Advanced Sinonasal Teratocarcinosarcoma

a Rare Malignancy: An Audit From an Academic Tertiary Care Centre in India. *Clinical Oncology* 36 (2024) e137-e145.

K. Vanita Noronha, Vijay Patil, Pankaj Chaturvedi, Vijayalakshmi Mathrudev, Nandini Menon, Atanu Bhattacharjee, Ajay Singh, Zoya Peelay, Shatabdi Chakraborty, Monica Jadhav, Mitali Alone, Priyanka Bhagyavant, Manali Kolkur, Sujay Srinivas, Sudeep Das, Somnath Roy, Tanmoy Mandal, Hollis Dsouza, **Saswata Saha**, Rahul Rai, Anne Srikanth, Darshit Shah, Arif Khan, Hemanth Muthuluri, Amit Kumar, Amit Agarwal, Anu Rajpurohit, Vasu Babu Goli, Anbarasan Sekar, Anoop Mantri, Aditya Pavan Kumar Kanteti, Swaratika Majumdar, Satvik Khaddar, Ramnath Shenoy, Prahlad Elamarthi, Narmadha Rathnasamy, Lakhan Kashyap, George Abraham, Naveen Booma, Vijay Simha, Devendra Chaukar, Prathamesh Pai, Sudhir Nair, Sarbani Laskar, Kavita Nawale, Priyanka Naidu, Sushmita Salian, Priyanka Shelar, Ravinarayan Raulo, Sachin Babanrao Dhumal and Kumar Prabhash. Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer. *European Journal of Cancer*, 2024-03-01, Volume 200, Article 113560.

L. Jessy Xinyi Han, Min Jung Koh, Leora Boussi, Mark Sorial, Sean M. McCabe, Luke Peng, Shambhavi Singh, Ijeoma Julie Eche-Ugwu, Judith Gabler, Maria J. Fernandez Turizo, Caroline T. MacVicar, Aditya Garg, Alexander Disciullo, Kusha Chopra, Alexandra Lenart, Emmanuel Nwodo, Jeffrey Barnes, Min Ji Koh, Eliana Miranda, Carlos Chiattonne, Robert Stuver, Steven M. Horwitz, Mwanasha Merrill, Eric Jacobsen, Martina Manni, Monica Civallero, Tetiana Skrypets, Athina Lymboussaki, Massimo Federico, Yuri Kim, Jin Seok Kim, Jae Yong Cho, Thomas Eipe, Tanuja Shet, Epari Sridhar, Alok Shetty, **Saswata Saha**, Hasmukh Jain, Manju Sengar, Carrie Van Der Weyden, Henry Miles Prince, Ramzi Hamouche, Tinatin Murdashvili, Francine Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won-Seog Kim,

Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al-Mansour, Josie Ford, Maria Elena Cabrera, Amy Ku, Govind Bhagat, Helen Ma, Ahmed Sawas, Khyati Maulik Kariya, Makoto Iwasaki, Forum Bhanushali, Owen A. O'Connor, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain; Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium. Blood Adv 2025; 9 (3): 583–602.

M. Saswata Saha, Disha Jain, Prashant Tembhare, Nishant Jindal, Puja Ramchandra Bhuibhar, Libin Jacob Mathew, Sumeet Mirgh, Akanksha Chichra, Lingaraj Nayak, Anant Gokarn, Sachin Punatar, Bhausahab Bagal, Sweta Rajpal, Gaurav Chatterjee, Nikhil Patkar, Papagudi Ganesan Subramanian, Hari Menon, Navin Khattri; Early Immune Reconstitution Post Allogeneic Transplant and Its Impact on Outcomes According to Type of Transplant. Blood 2024; 144 (Supplement 1): 7352.

Oral Presentations:

A. Final OS results and subgroup analysis of savolitinib in patients with MET Exon 14 Skipping Mutations (METex14+) NSCLC – 6th Annual Year End Review in Lung Cancer

B. Trastuzumab Deruxtecan in Her 2-Mutant Non-Small-Cell Lung Cancer – 6th Annual Year End Review in Lung Cancer

C. Real World Data on Demographics, Management and Outcome of Ultra High-Risk Myeloma - Experience from a Tertiary Care Centre – Indian Myeloma Congress 2024 (6th Annual Conference of IMAGE)

D. Case presentation on the topic Chronic GVHD – 5th Annual Meeting of the Indian Society for Blood and Marrow Transplantation (ISBMT 2024)

Clinical Trials:

1. Single center phase II study to determine safety and efficacy of Letermovir for the prevention of clinically significant Cytomegalovirus (CMV) infection in Adult, CMV-Seropositive allogeneic HSCT Recipients. **(Principal Investigator)**
2. A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1). **(Co-Investigator)**
3. A Phase 1/2, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of DRL-1801 in Patients with RRMM (SWASTH). **(Co-Investigator)**
4. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1). **(Co-Investigator)**
5. A Double-Blind, Randomized clinical study of the efficacy and safety of monotherapy with BCD-264 and Darzalex® in subjects with Relapsed and Refractory Multiple Myeloma (DARVIVA). **(Co-Investigator)**


30-MAR-2026



NIDA Clinical Trials Network

Certificate of Completion

is hereby granted to
Saswata Saha
to certify your completion of the six-hour required course on:

GOOD CLINICAL PRACTICE

MODULE:	STATUS:
Introduction	N/A
Institutional Review Boards	Passed
Informed Consent	Passed
Confidentiality & Privacy	Passed
Participant Safety & Adverse Events	Passed
Quality Assurance	Passed
The Research Protocol	Passed
Documentation & Record-Keeping	Passed
Research Misconduct	Passed
Roles & Responsibilities	Passed
Recruitment & Retention	Passed
Investigational New Drugs	Passed

Course Completion Date: 27 December 2024

CTN Expiration Date: 27 December 2027

Eve Jelstrom

Eve Jelstrom, Principal Investigator
NDAT CTN Clinical Coordinating Center

Good Clinical Practice, Version 5, effective 03-Mar-2017

This training has been funded in whole or in part with Federal funds from the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN27201201000024C.

Saswata Saha
30-MAR-2026



West Bengal Medical Council

IB 196, Sector III, Salt Lake, Kolkata - 700106

E-mail: wmmc@wmmc.in • Website: www.wmmc.wb.gov.in

CERTIFICATE FOR REGISTRATION OF ADDITIONAL QUALIFICATION

Date: 26/09/2024



WBMC Registration No. : 70740

Saxena Sahu

Date of Original Registration

: 04/04/2014

Name

: SAHA,
DR. SASWATA

Father's Name

: SRI BANESWAR SAHA

Sex

: MALE

Address

: Permanent:

GURUPALLI (SOUTH), SANTINIKETAN, BOLPUR, BIRBHUM : 731
235.

Present:

MADUMALANCHA APARTMENT, C BLOCK 4TH FLOOR 501, 262
PULIN AVENUE, DUMDUM, RAJBARI COLONY, AIRPORT, NORTH
24 PARGANAS, WEST BENGAL,
PIN/ZIP-700081, INDIA

Qualification

: Basic:

M B B S (WEST BENGAL UNIVERSITY OF HEALTH SCIENCES),
2014

Additional:

- M D (General Medicine) (BANARAS HINDU UNIVERSITY), 2018
[REGD ON: 26/09/2024]

- D M (Medical Oncology) (HOMI BHABHA NATIONAL INSTITUTE),
2022 [REGD ON: 26/09/2024]

Validity unknown

Digitally Signed
Signed by: MANAS CHAKRABORTY
Reason: Sign,Addl.Cert.
Location: wmmc
Date: 26-Sep-2024 16:30:30



Signature of the Registrar
West Bengal Medical Council

Saxena Sahu
30-MAR-2026